World's Best Scientists 2026 revealed!
Michael Kneba

Michael Kneba

D-Index & Metrics

Medicine

D-Index
92
Citations
46749
World Ranking
11092
National Ranking
600

Overview

Michael Kneba is affiliated with Kiel University in Germany and specializes in medical research with a focus on hematology and oncology. Their work primarily explores genetic, pathological, immunological, and oncological aspects within medicine.

Kneba's research spans several key scientific topics including:

  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Immunodeficiency and Autoimmune Disorders
  • CNS Lymphoma Diagnosis and Treatment
  • Glioma Diagnosis and Treatment
  • Advanced Breast Cancer Therapies
  • Gastrointestinal Tumor Research and Treatment

The scientist has contributed to recent publications such as:

  • The Genomic and Transcriptional Landscape of Primary Central Nervous System Lymphoma (2022, Nature Communications)
  • Prognostic and Predictive Impact of Genetic Markers in Patients with CLL Treated with Obinutuzumab and Venetoclax (2020, Blood)
  • Early Treatment with FCR versus Watch and Wait in Patients with Stage Binet A High-Risk Chronic Lymphocytic Leukemia: A Randomized Phase 3 Trial (2020, Leukemia)
  • Obinutuzumab (GA-101), Ibrutinib, and Venetoclax (GIVe) Frontline Treatment for High-Risk Chronic Lymphocytic Leukemia (2022, Blood)
  • Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG) (2020, HemaSphere)

Frequent collaborators include:

  • Stephan Stilgenbauer
  • Barbara Eichhorst
  • Kirsten Fischer
  • Michael Hallek
  • Eugen Tausch

Kneba's work has appeared most often in the following scientific journals:

  • Blood
  • HemaSphere
  • Hematological Oncology
  • Nature Communications
  • Leukemia

Their contributions have largely focused on subfields including Genetics, Pathology and Forensic Medicine, Immunology, Oncology, and Neurology, with a significant number in genetic research related to hematological cancers.

Best Publications

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

    J J M van Dongen;A W Langerak;M Brüggemann;P A S Evans

  • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

    Michael Hallek;K. Fischer;Gunter Fingerle-Rowson;A.M. Fink

  • Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

    Salah-Eddin Al-Batran;Nils Homann;Claudia Pauligk;Thorsten O Goetze

  • Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

    Wolfgang Hiddemann;Michael Kneba;Martin Dreyling;Norbert Schmitz

  • Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

    Valentin Goede;Kirsten Fischer;Raymonde Busch;Anja Engelke

  • The landscape of genomic alterations across childhood cancers

    Susanne N. Gröbner;Barbara C. Worst;Joachim Weischenfeldt;Joachim Weischenfeldt;Ivo Buchhalter

  • Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

    Max S. Topp;Peter Kufer;Nicola Gökbuget;Mariele Goebeler

  • Mutations driving CLL and their evolution in progression and relapse.

    Dan A. Landau;Eugen Tausch;Amaro N. Taylor-Weiner;Chip Stewart

  • ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology

    J. Arends;G. Bodoky;F. Bozzetti;K.C. Fearon

  • Patterns of somatic structural variation in human cancer genomes

    Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

  • Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

    Andreas Engert;Heinz Haverkamp;Carsten Kobe;Jana Markova

  • Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

    Kirsten Fischer;Jasmin Bahlo;Anna Maria Fink;Valentin Goede

  • First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.

    Barbara Eichhorst;Anna-Maria Fink;Jasmin Bahlo;Raymonde Busch

  • Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

    Monika Brüggemann;Thorsten Raff;Thomas Flohr;Nicola Gökbuget

  • Gene mutations and treatment outcome in chronic lymphocytic leukemia: Results from the CLL8 trial

    Stephan Stilgenbauer;Andrea Schnaiter;Peter Paschka;Thorsten Zenz;Thorsten Zenz

  • Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.

    Sebastian Böttcher;Matthias Ritgen;Kirsten Fischer;Stephan Stilgenbauer

  • Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

    Kirsten Fischer;Paula Cramer;Raymonde Busch;Sebastian Böttcher

  • Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

    Max S. Topp;Nicola Gökbuget;Gerhard Zugmaier;Evelyn Degenhard

  • Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.

    Nicola Gökbuget;Michael Kneba;Thorsten Raff;Heiko Trautmann

Frequent Co-Authors

Michael Hallek
Michael Hallek University of Cologne
Hartmut Döhner
Hartmut Döhner University of Ulm
Stephan Stilgenbauer
Stephan Stilgenbauer University of Ulm
Michael Pfreundschuh
Michael Pfreundschuh Saarland University
Raymonde Busch
Raymonde Busch Technical University of Munich
Wolfgang Hiddemann
Wolfgang Hiddemann Ludwig-Maximilians-Universität München
Martin Dreyling
Martin Dreyling Ludwig-Maximilians-Universität München
Wolfram Klapper
Wolfram Klapper Kiel University
Lothar Kanz
Lothar Kanz University of Tübingen
Norbert Schmitz
Norbert Schmitz University of Münster

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Medicine in the USA opens doors to a variety of related, flexible online degrees and career pathways. For those interested in holistic health and disease prevention, earning the best online nutrition degree can provide a strong foundation in nutritional science—with the added convenience of remote study.

Aspiring healthcare administrators can advance their careers with a degree from cahme-accredited online Master of Health Administration (MHA) programs, ensuring quality education and greater job prospects. Meanwhile, registered nurses looking for career progression might consider online rn to bsn programs without clinical requirements, which offer a flexible route to enhance credentials.

For advanced practice nurses, earning a Doctor of Nursing Practice is more accessible than ever—some options include a 1 year dnp program online, enabling swift advancement to leadership roles. No matter your focus, there are diverse, accredited online pathways to grow your medical career in the USA.

Best Scientists Citing Michael Kneba

Trending Scientists